✓
Open
1 Nov 2021
✓
Close
3 Nov 2021
3
Allotment
—
✓
Listing
Mon, Nov 15, 2021
Price Band
₹161 to ₹163
Issue Size
76,95,000 shares (agg. up to ₹125 Cr)
Lot Size
90 Shares
Listing Date
Mon, Nov 15, 2021
Latest GMP
₹225
Est. Gain
138.04%
✦ AI Insight
GMP Trend
15-11-2021₹225Est. ₹388+138.04%
12-11-2021₹210Est. ₹373+128.83%
11-11-2021₹210Est. ₹373+128.83%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 64.89x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Jun 2021 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|---|
| Assets | 151.42 | 133.41 | 109.14 | 91.46 |
| Total Income | 55.12 | 196.01 | 143.95 | 132.88 |
| Profit After Tax | 8.99 | 30.26 | 20.32 | 19.01 |
| EBITDA | 12.38 | 42.04 | 29.65 | 29.85 |
| NET Worth | 103.24 | 94.20 | 64.59 | 44.88 |
| Reserves and Surplus | 95.56 | 86.52 | 56.90 | 41.81 |
| Total Borrowing | 25.59 | 20.93 | 30.38 | 25.19 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Ami Organics Ltd. | Mainboard | ₹569.64 Cr | ₹610 | null | ₹935.00 | +53.28% | ₹3,583.80 (+1.01%) |
| Windlas Biotech Ltd. | Mainboard | ₹401.54 Cr | ₹460 | null | ₹407.15 | -11.49% | ₹850.25 (+1.16%) |
| Glenmark Life Sciences Ltd. | Mainboard | ₹1,513.60 Cr | ₹720 | null | ₹748.50 | +3.96% | ₹1,164.10 (-0.31%) |
| Gland Pharma Ltd. | Mainboard | ₹6,479.55 Cr | ₹1500 | null | ₹1,819.55 | +21.30% | ₹2,529.40 (+2.81%) |
| Walpar Nutritions Ltd. | SME | ₹6.60 Cr | ₹55 | null | ₹57.00 | +3.64% | ₹34.50 (+0.00%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure for expansion of production capacity for MCC at Dahej, Gujarat | 28.16 |
| 2 | Funding capital expenditure for expansion of production capacity for MCC at Jhagadia, Gujarat | 29.24 |
| 3 | Funding capital expenditure to manufacture CCS at the Proposed Unit | 32.30 |
| 4 | General corporate purposes | 20.43 |
About Sigachi Industries IPO
Incorporated in 1989, Sigachi Industries is engaged in manufacturing of Microcrystalline Cellulose (MCC) which is widely used as an excipient for finished dosages in the pharmaceutical industry. MCC has varied applications in the pharmaceutical, food, nutraceuticals, and cosmetic industries. The company manufactures MCC of various grades ranging from 15 microns to 250 microns and the major grades of MCC manufactured and marketed by the company are branded as HiCel and AceCel. Presently, the company manufactures 59 different grades of MCC at the manufacturing units, situated in Hyderabad and Gujarat. The company has an in-house R&D division equipped with the necessary facilities to carry out all necessary trials to develop new molecules from concept to commissioning. The company has received various quality certifications and operates 3 manufacturing units namely, Unit I situated at Hyderabad, and two manufacturing units, Unit II and Unit III situated at Jhagadia and Dahej, in Gujarat. As of March 31, 2021, company's total MCC manufacturing capacity is 13,128 MTPA from three locations. Competitive Strengths: One of the leading manufacturers of MCC in India. Long-standing market pres
Contact Details
Sigachi Industries Ltd. Address229/1 & 90, Kalyan’s Tulsiram ChambersMadinagudaHyderabad, Telangana, 500049+91 040 4011 4874cs@sigachi.comVisit Website